Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis.

Hoeman CM, Cordero FJ, Hu G, Misuraca K, Romero MM, Cardona HJ, Nazarian J, Hashizume R, McLendon R, Yu P, Procissi D, Gadd S, Becher OJ.

Nat Commun. 2019 Mar 4;10(1):1023. doi: 10.1038/s41467-019-08823-9.

2.

Histone H3.3K27M Represses p16 to Accelerate Gliomagenesis in a Murine Model of DIPG.

Cordero FJ, Huang Z, Grenier C, He X, Hu G, McLendon RE, Murphy SK, Hashizume R, Becher OJ.

Mol Cancer Res. 2017 Sep;15(9):1243-1254. doi: 10.1158/1541-7786.MCR-16-0389. Epub 2017 May 18.

3.

Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma.

Subashi E, Cordero FJ, Halvorson KG, Qi Y, Nouls JC, Becher OJ, Johnson GA.

J Neurooncol. 2016 Jan;126(2):243-51. doi: 10.1007/s11060-015-1969-9. Epub 2015 Oct 28.

4.

Pre-Clinical Models of Diffuse Intrinsic Pontine Glioma.

Misuraca KL, Cordero FJ, Becher OJ.

Front Oncol. 2015 Jul 24;5:172. doi: 10.3389/fonc.2015.00172. eCollection 2015. Review.

5.

A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent.

Halvorson KG, Barton KL, Schroeder K, Misuraca KL, Hoeman C, Chung A, Crabtree DM, Cordero FJ, Singh R, Spasojevic I, Berlow N, Pal R, Becher OJ.

PLoS One. 2015 Mar 6;10(3):e0118926. doi: 10.1371/journal.pone.0118926. eCollection 2015.

Supplemental Content

Loading ...
Support Center